Journal for ImmunoTherapy of Cancer · 2024 · 29 citations · 26 references
Life SciencesImmunologyImmunotechnologyImmunotherapySolid Tumor PharmacotherapyAntitumor T Cell ResponsesChimeric Antigen Receptor T-cell TherapyCytokine-based TherapyImmunotherapy For Solid TumorsT Cell Responses To TumorsTumor-associated AntigensChimeric Antigen Receptor T Cell Combination TherapyCombination Cell TherapyCytokine Targeted TherapyOrthotopic Tumor ModelsSolid Tumor ApplicationsSolid Tumor Car T-cell TherapySolid Tumor Cell TherapyTumor Antigen-based Immunotherapy
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable remission in patients with B-cell malignancies. However, its efficacy in treating solid tumors remains limited. Here, we investigated a combination therapy approach using an engineered long-acting interleukin (IL)-7 (rhIL-7-hyFc or NT-I7) and CAR-T cells targeting three antigens, glypican-2 (GPC2), glypican-3 (GPC3), and mesothelin (MSLN), against multiple solid tumor types including liver cancer, neuroblastoma, ovarian cancer, and pancreatic cancer in mice. METHODS: CAR-T cells targeting GPC2, GPC3, and MSLN were used in combination with NT-I7 to assess the anticancer activity. Xenograft tumor models, including the liver cancer orthotopic model, were established using NOD scid gamma mice engrafted with cell lines derived from hepatocellular carcinoma, neuroblastoma, ovarian cancer, and pancreatic cancer. The mice were monitored by bioluminescence in vivo tumor imaging and tumor volume measurement using a caliper. Immunophenotyping of CAR-T cells on NT-I7 stimulation was evaluated for memory markers, exhaust markers, and T-cell signaling molecules by flow cytometry and western blotting. RESULTS: CAR-T, improved T-cell expansion, reduced exhaustion markers (programmed cell death protein 1 or PD-1 and lymphocyte-activation gene 3 or LAG-3) expression, and increased generation of stem cell-like memory CAR-T cells. The STAT5 pathway was demonstrated to be downstream of NT-I7 signaling, mediated by increased expression of the IL-7 receptor expression in CAR-T cells. Furthermore, CAR-T cells improved efficacy against tumors with low antigen density when combined with NT-I7 in mice, presenting an avenue for patients with heterogeneous antigenic profiles. CONCLUSION: This study provides a rationale for NT-I7 plus CAR-T cell combination therapy for solid tumors in humans.
26
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
J. Joseph Melenhorst, Gregory M. Chen, Meng Wang et al. · Nature · 2022 · 920 citations · Full text
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Nicoletta Cieri, Barbara Camisa, Fabienne Cocchiarella et al. · Blood · 2012 · 606 citations · Full text
Fiona Thistlethwaite, David E. Gilham, Ryan D. Guest et al. · Cancer Immunology Immunotherapy · 2017 · 409 citations · Full text
Life Sciences, Immunology, Oncology +17